Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Position Reduced by Braidwell LP

Braidwell LP cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 99.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 370,400 shares of the biotechnology company’s stock after selling 42,777,500 shares during the period. Sarepta Therapeutics comprises approximately 1.3% of Braidwell LP’s holdings, making the stock its 29th largest position. Braidwell LP’s holdings in Sarepta Therapeutics were worth $46,259,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Tidal Investments LLC grew its position in Sarepta Therapeutics by 8.5% during the first quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 228 shares in the last quarter. Comerica Bank boosted its holdings in shares of Sarepta Therapeutics by 489.4% during the 1st quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock worth $432,000 after buying an additional 2,770 shares during the period. Cetera Investment Advisers boosted its holdings in shares of Sarepta Therapeutics by 27.6% during the 1st quarter. Cetera Investment Advisers now owns 11,991 shares of the biotechnology company’s stock worth $1,552,000 after buying an additional 2,590 shares during the period. Garde Capital Inc. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $140,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Sarepta Therapeutics by 91.9% during the 2nd quarter. GAMMA Investing LLC now owns 618 shares of the biotechnology company’s stock worth $98,000 after buying an additional 296 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SRPT. Robert W. Baird decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. HC Wainwright began coverage on shares of Sarepta Therapeutics in a report on Monday. They set a “sell” rating and a $80.00 price objective for the company. UBS Group upped their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Needham & Company LLC cut their target price on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Piper Sandler cut their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $137.94 on Friday. The business’s 50-day moving average price is $122.16 and its two-hundred day moving average price is $131.43. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market cap of $13.18 billion, a PE ratio of 110.35 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1-year low of $78.67 and a 1-year high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.